Akcea Therapeutics and Ionis about their Phase 3 clinical trial to evaluate a new drug for amyloid cardiomyopathy quotes Stephen Heitner, M.D.

OHSU Knight Cancer Institute researchers contribute to Nature Biotechnology paper outlining a new framework to estimate how fast an individual cancer has evolved using open-source software.

Alan Teo, M.D., and colleagues publish new definition of hikikomori, or extreme isolation, to improve the recognition and treatment of the condition.

Molly Hubbard, M.D., a pediatric neurosurgery fellow recently hired as a faculty member, died this week in an avalanche while skiing near Kellogg, Idaho.

12-year-old Medford, Oregon, boy treated at Doernbecher for flesh-eating bacteria.

Happy Valley toddler receives kidney from mom at Doernbecher.

Blueprint Medicines announces FDA approval of AYVAKIT, a drug for patients with a form of gastrointestinal stromal tumor, or GIST; study investigator Michael Heinrich, M.D., says: “Building on our growing understanding of the molecular basis of GIST, this milestone ushers in a new era of precision medicine in this disease.”

Study investigator Michael Heinrich, M.D., comments on Blueprint Medicines announcement of FDA approval of AYVAKIT, a drug for patients with a form of gastrointestinal stromal tumor, or GIST.

Research led by Mark Slifka, Ph.D., finds HIV patients being treated with antiretroviral therapy lose their immunity to smallpox despite having received a childhood vaccination against the disease.

Esther Choo, M.D., is one of several national experts asked to predict what’s next for their respective industry’s workplace.